also relapsed 4 The objective of this review is to find out what evidence exists for relapse of illness after discontinuation of lithium that has been taken as a successful treatment for unipolar depression in the geriatric population, whether they started lithium as a younger adult or as a geriatric patient.
Method
A literature search was completed using MEDLINE, PsycINFO, EMBASE, and the Cochrane database from January 1985 to October 2006. The search terms used were lithium and depression and discontinuation and elderly. Substitution of geriatric for elderly and the addition of the term augmentation did not yield further results. Bibliographies of all articles found were searched for further references and a review of the adult literature was done for geriatric subanalyses. Articles were selected based on selection criteria for relevance and design quality (original studies, French or English, patients older than 65 years, patients with an episode of MDD meeting DSM-III or greater criteria, and patients who had been successfully treated to remission with lithium augmentation of an antidepressant, then withdrawn from lithium augmentation treatment). An expert in the field was also contacted. We reviewed the results from these studies for quality using criteria from the evidence-based working group and relevant data were compiled.
Data Extraction
Studies were screened for design, number of patients, length of follow-up, and depression diagnosis. Studies were reviewed for relapse rates among those who had been exposed to withdrawal of lithium.
Study Quality
Evidence-based criteria were used to evaluate studies. For an article about therapy, the model of the McMaster EBMWG was used to evaluate the data. 5, 6 The criteria are outlined in the cited reference. Size of treatment effect and benefits being worth the risk were not scored as they are a reflection of results and not study design.
Results
Three studies were found (see Table 1 ). The earliest study had limited results. 7 Treatment and withdrawal from treatment were investigated in multiple arms with small numbers of geriatric patients on different augmentation medications for unipolar depression. Among those receiving lithium as augmentation specifically, the rate of relapse after discontinuation was 45.5% and was not significantly different from perphenazine alone or perphenazine plus lithium.
Overall, 52% of those receiving augmentation relapsed over the continuation (that is, discontinuation of augmentation) phase. They concluded that one-half of elderly patients who require adjunctive medication to achieve remission from unipolar depression might require to be maintained on the augmentation medication as well.
This paper was not randomized. Those who failed a previous treatment arm were given augmentation. Augmentation was only continued for 4 to 6 weeks then discontinued, which is not usual treatment. It was not stated if all of the original subjects were accounted for at the end of the trial. Treatment was not blinded, which reduced the usefulness of comparing the 2 groups' outcomes.
The next study was rigorously designed and focused (the only RCT), but had inconclusive results. 4 W La Revue canadienne de psychiatrie, vol 53, no 2, février 2008 118 Two patients from each study arm (randomized to continue with lithium augmentation or to placebo) relapsed into depression. There were significant stressors in the 2 patients who relapsed into depression in the lithium group but no significant stressors were identified among those who relapsed in the placebo group.
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The third study was a naturalistic study of lithium discontinuation from a lithium clinic in Ireland. 8 Eleven or 52.4% of patients relapsed after discontinuation in a mean time of 7.8 months (SD 9.1 months). The nonrelapse group was followed for a total of 19.5 months. Those who relapsed after discontinuation were found to have been on lithium augmentation for a significantly longer period of time (mean 2.5 years, SD 0.95) than those who did not relapse (mean 1.35 years, SD 0.74). Those who relapsed off lithium also had a trend toward a history of more hospital admissions.
Study Quality
Studies were scored as described above. Fahy and Lawlor's study 8 was a naturalistic design and scored poorly on the EBMWG criteria because it was not randomized and had no control group. The information taken from it was useful as the design was otherwise rigorous and evaluated effectiveness rather than efficacy. Almost all patients were women and one-third had psychotic features, which detracted from the overall applicability of the information. The study of Reynolds et al 7 was of less rigorous design and had ambiguous results with limited usefulness concerning the specific question.
Discussion
The 3 studies had small sample sizes and very different methodologies. This created a significant statistical weakness. It was uncertain if the outcomes were significant or not.
Reynolds et al 7 had the weakest data set and their results were obfuscated by the complexity of their design.
It is notable that the lithium augmentation strategy used was not in keeping with standard practice and that those on lithium were sicker to begin with. Hardy et al 4 had the best trial design, which allowed for a direct comparison between withdrawal of treatment and maintenance of treatment. Their stringent admission criteria led to the trial having only 12 participants, with 6 who were withdrawn from lithium augmentation.
The overall results, when taken purely statistically, suggested that lithium augmentation was without therapeutic value in the maintenance phase of unipolar depression as there were no difference between groups. Further, mean composite side effect scores were significantly lower in the placebo group, compared with the lithium group.
The 2 patients who suffered relapses had significant adverse events in the time leading up to their relapse, whereas it appeared as though those who relapsed in the placebo arm did not. The small numbers in the trial did not give the study the overall power to find a difference between the 2 groups and random events had a disproportionate effect on the outcome in favour of placebo. As a strict RCT, this study is also limited in its applicability to real-world situations.
Fahy and Lawlor's study 8 used a naturalistic study design, which was more revealing of true effectiveness than an RCT. Some of their statistical findings were rather obscure. They attempted to extract findings as to which factors would predict a relapse after the withdrawal of lithium in this population. Their findings suggested that those who had more hospitalizations in the past (that is, more severe illness) and those who had been on lithium longer were more likely to relapse; however, they did not find any predictive demographic factors. They had the largest number of patients and found a relapse rate of 52.4% over a median of 7 months. The absence of a control arm made the outcome less statistically useful.
Overall, the rate of relapse of major depression in the geriatric population after withdrawal of lithium augmentation appears to be roughly equivalent to that seen in the younger adult population, around 50% that Hardy et al 4 cites, although given the different time frames of the various studies, this would be in a period of anywhere from 12 to 49 weeks (average length of follow-up is 31 weeks, just over 6 months). It is uncertain how this figure would compare with relapse rates had the patient been kept on lithium. The only study that might have been able to answer that question, that of Hardy et al, 4 had too few participants and too little power to address the question with any certainty.
This study had several limitations in its design and execution.
Because of the specificity of the question (unipolar depression and geriatric patients) the results of the search were quite limited. As discussed above, the results of those studies were in turn limited by small patient populations. Moreover, the design of this study was limited in its literature search as conference abstracts and databases of unpublished studies were not consulted for results. The limitations of the data available also limited the amount of statistical information that could be gleaned from the results such as an accurate overall odds ratio. 
Conclusion
The results of this review of the geriatric literature suggest that there may be a relapse rate of up to 50% after the withdrawal of lithium augmentation within 6 months. Unfortunately, owing to the inconsistent methodologies used in the 3 major studies found and the small numbers involved, this is not a statement that can be made with a large degree of certainty or precision, yet it appears to be a consistent trend. Therefore, there is room for future investigation of the question of how large the relapse rate is in elderly patients who have been taken off of lithium augmentation. Larger, more systematic studies are needed.
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Résumé : Interruption de l'augmentation au lithium chez les patients gériatriques souffrant de dépression unipolaire : une étude systématique
Objectif : Le lithium est une stratégie d'augmentation pour la dépression unipolaire chez les populations gériatriques. Cette étude présente les données probantes de la documentation concernant le risque de rechute lorsque le lithium est interrompu chez les patients gériatriques.
Méthode : Les articles ont été choisis d'après des critères de sélection pour leur utilité et la qualité de leur méthodologie (études originales, en français ou en anglais, patients de plus de 65 ans, patients ayant un épisode de dépression majeure satisfaisant aux critères du DSM-III ou ultérieur, et patients traités vers une rémission réussie par une augmentation au lithium d'un antidépresseur, puis sevrés de l'augmentation au lithium).
Résultats :
Trois articles ont été trouvés. Le taux global de rechute n'a pas pu être clairement établi, mais un taux de rechute de 50 % sur environ 6 mois de suivi pouvait être prévu d'après les résultats de l'étude.
Conclusions :
Il y a un risque de rechute chez les patients âgés dont le traitement d'augmentation au lithium pour la dépression unipolaire est interrompu. Il faut plus d'essais randomisés contrôlés pour fournir des renseignements plus déterminants à ce sujet.
